vs
MYOMO, INC.（MYO）与Research Solutions, Inc.（RSSS）财务数据对比。点击上方公司名可切换其他公司
Research Solutions, Inc.的季度营收约是MYOMO, INC.的1.0倍（$11.8M vs $11.4M），Research Solutions, Inc.净利率更高（4.6% vs -33.6%，领先38.2%），Research Solutions, Inc.同比增速更快（-1.0% vs -5.9%），Research Solutions, Inc.自由现金流更多（$1.4M vs $-2.4M），过去两年MYOMO, INC.的营收复合增速更高（73.9% vs -1.3%）
MYOMO INC.是一家医疗科技企业，研发和生产可穿戴肌电矫形设备，帮助上肢瘫痪或无力的患者恢复肢体活动能力，核心产品面向中风、脊髓损伤及其他神经系统疾病患者，主要市场覆盖北美地区。
雅各布斯解决方案是一家总部位于美国达拉斯的国际技术专业服务企业，面向全球各类客户（包括企业、机构及政府部门）提供工程、技术、专业、建筑相关服务，以及科研与专项咨询服务，常年位居《工程新闻纪录》顶级设计企业榜单榜首。
MYO vs RSSS — 直观对比
营收规模更大
RSSS
是对方的1.0倍
$11.4M
营收增速更快
RSSS
高出4.9%
-5.9%
净利率更高
RSSS
高出38.2%
-33.6%
自由现金流更多
RSSS
多$3.8M
$-2.4M
两年增速更快
MYO
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.4M | $11.8M |
| 净利润 | $-3.8M | $546.9K |
| 毛利率 | 68.6% | 52.4% |
| 营业利润率 | -24.4% | 6.3% |
| 净利率 | -33.6% | 4.6% |
| 营收同比 | -5.9% | -1.0% |
| 净利润同比 | -1366.4% | 127.6% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYORSSS
| Q4 25 | $11.4M | $11.8M | ||
| Q3 25 | $10.1M | $12.3M | ||
| Q2 25 | $9.7M | $12.4M | ||
| Q1 25 | $9.8M | $12.7M | ||
| Q4 24 | $12.1M | $11.9M | ||
| Q3 24 | $9.2M | $12.0M | ||
| Q2 24 | $7.5M | $12.1M | ||
| Q1 24 | $3.8M | $12.1M |
净利润MYORSSS
| Q4 25 | $-3.8M | $546.9K | ||
| Q3 25 | $-3.7M | $749.4K | ||
| Q2 25 | $-4.6M | $2.4M | ||
| Q1 25 | $-3.5M | $216.5K | ||
| Q4 24 | $-260.1K | $-2.0M | ||
| Q3 24 | $-966.4K | $669.0K | ||
| Q2 24 | $-1.1M | $-2.8M | ||
| Q1 24 | $-3.8M | $76.3K |
毛利率MYORSSS
| Q4 25 | 68.6% | 52.4% | ||
| Q3 25 | 63.8% | 50.6% | ||
| Q2 25 | 62.7% | 51.0% | ||
| Q1 25 | 67.2% | 49.5% | ||
| Q4 24 | 71.4% | 48.9% | ||
| Q3 24 | 75.4% | 47.9% | ||
| Q2 24 | 70.8% | 46.5% | ||
| Q1 24 | 61.2% | 45.2% |
营业利润率MYORSSS
| Q4 25 | -24.4% | 6.3% | ||
| Q3 25 | -34.9% | 7.8% | ||
| Q2 25 | -47.6% | 9.7% | ||
| Q1 25 | -35.8% | 4.4% | ||
| Q4 24 | -2.0% | 0.8% | ||
| Q3 24 | -10.4% | 5.4% | ||
| Q2 24 | -14.8% | 5.5% | ||
| Q1 24 | -103.6% | 0.7% |
净利率MYORSSS
| Q4 25 | -33.6% | 4.6% | ||
| Q3 25 | -36.3% | 6.1% | ||
| Q2 25 | -48.0% | 19.0% | ||
| Q1 25 | -35.2% | 1.7% | ||
| Q4 24 | -2.2% | -16.6% | ||
| Q3 24 | -10.5% | 5.6% | ||
| Q2 24 | -14.9% | -23.3% | ||
| Q1 24 | -102.2% | 0.6% |
每股收益（稀释后）MYORSSS
| Q4 25 | $-0.09 | $0.02 | ||
| Q3 25 | $-0.09 | $0.02 | ||
| Q2 25 | $-0.11 | $0.08 | ||
| Q1 25 | $-0.08 | $0.01 | ||
| Q4 24 | $0.00 | $-0.07 | ||
| Q3 24 | $-0.03 | $0.02 | ||
| Q2 24 | $-0.03 | $-0.09 | ||
| Q1 24 | $-0.10 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.4M | $12.3M |
| 总债务越低越好 | $11.2M | — |
| 股东权益账面价值 | $11.4M | $17.2M |
| 总资产 | $38.6M | $44.2M |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资MYORSSS
| Q4 25 | $18.4M | $12.3M | ||
| Q3 25 | $12.6M | $12.0M | ||
| Q2 25 | $15.5M | $12.2M | ||
| Q1 25 | $21.5M | $9.9M | ||
| Q4 24 | $24.9M | $7.7M | ||
| Q3 24 | $6.6M | $6.9M | ||
| Q2 24 | $9.0M | $6.1M | ||
| Q1 24 | $11.0M | $4.2M |
总债务MYORSSS
| Q4 25 | $11.2M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MYORSSS
| Q4 25 | $11.4M | $17.2M | ||
| Q3 25 | $14.6M | $15.6M | ||
| Q2 25 | $17.6M | $13.9M | ||
| Q1 25 | $21.7M | $11.2M | ||
| Q4 24 | $24.7M | $11.1M | ||
| Q3 24 | $9.3M | $12.8M | ||
| Q2 24 | $9.7M | $11.7M | ||
| Q1 24 | $10.9M | $14.1M |
总资产MYORSSS
| Q4 25 | $38.6M | $44.2M | ||
| Q3 25 | $34.1M | $45.5M | ||
| Q2 25 | $38.7M | $46.1M | ||
| Q1 25 | $40.9M | $45.2M | ||
| Q4 24 | $42.2M | $42.8M | ||
| Q3 24 | $16.3M | $41.4M | ||
| Q2 24 | $16.2M | $41.9M | ||
| Q1 24 | $16.5M | $40.8M |
负债/权益比MYORSSS
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $1.4M |
| 自由现金流率自由现金流/营收 | -21.0% | 11.7% |
| 资本支出强度资本支出/营收 | 10.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | $-18.7M | — |
8季度趋势，按日历期对齐
经营现金流MYORSSS
| Q4 25 | $-1.1M | $1.4M | ||
| Q3 25 | $-1.8M | $1.1M | ||
| Q2 25 | $-8.9M | $2.3M | ||
| Q1 25 | $-2.7M | $2.9M | ||
| Q4 24 | $3.4M | $1.0M | ||
| Q3 24 | $-1.5M | $843.1K | ||
| Q2 24 | $-1.9M | $2.0M | ||
| Q1 24 | $-3.2M | $2.0M |
自由现金流MYORSSS
| Q4 25 | $-2.4M | $1.4M | ||
| Q3 25 | $-2.9M | $1.1M | ||
| Q2 25 | $-10.1M | — | ||
| Q1 25 | $-3.3M | $2.9M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-2.0M | $1.9M | ||
| Q1 24 | $-3.3M | $2.0M |
自由现金流率MYORSSS
| Q4 25 | -21.0% | 11.7% | ||
| Q3 25 | -28.6% | 8.8% | ||
| Q2 25 | -104.9% | — | ||
| Q1 25 | -34.0% | 22.8% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | -19.7% | — | ||
| Q2 24 | -27.1% | 16.0% | ||
| Q1 24 | -88.0% | 16.6% |
资本支出强度MYORSSS
| Q4 25 | 10.9% | 0.1% | ||
| Q3 25 | 10.4% | 0.1% | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 6.8% | 0.0% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 1.6% | 0.1% | ||
| Q1 24 | 1.6% | 0.0% |
现金转化率MYORSSS
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 13.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 26.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYO
| Direct To Patient | $7.9M | 69% |
| Clinical And Medical Providers | $3.5M | 31% |
RSSS
| Transactions | $6.6M | 56% |
| Platforms | $5.2M | 44% |
